Cystic Fibrosis Trust and NovaBiotics Enter Partnership for Phase IIa Clinical Trial

What happens when a cystic fibrosis charity and a biotechnology company team up through a partnership? The answer is a Phase IIa clinical trial in the United Kingdom put together by Cystic Fibrosis Trust and NovaBiotics. Also included in the effort are the University of Aberdeen, Health Continue reading Cystic Fibrosis Trust and NovaBiotics Enter Partnership for Phase IIa Clinical Trial

Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa.

Artilysins constitute a novel class of efficient enzyme-based antibacterials. Specifically, they covalently combine a bacteriophage-encoded endolysin, which degrades the peptidoglycan, with a targeting peptide that transports the endolysin through the outer membrane of Gram-negative Continue reading Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa.

New hope for cystic fibrosis patients in medication derived from Norwegian seaweed

* New drug could extend life expectancy for CF patients
* Active ingredient is carbohydrate found in Norwegian seaweed
* New drug could extend life expectancy for CF patients Continue reading New hope for cystic fibrosis patients in medication derived from Norwegian seaweed

Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption

After the Food and Drug Administration (FDA) issued rules requiring approval of pancreatic enzyme products (PEPs) in 2004, the cost and availability of the products added another hardship to the lives of cystic fibrosis patients, some of whom use PEPs to prevent uncomfortable and Continue reading Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption

Gilead’s AZLI Therapy For Treatment Of PALS In Cystic Fibrosis Deemed Safe, Effective In Recent Study

Following the recent success of a phase 3b clinical trial for Aztreonam in cystic fibrosis (CF) patients with Burkholderia infections, Gilead Sciences, Inc., a research-based biopharmaceutical company engaged in CF drug discovery and development, completed another phase 3 clinical trial Continue reading Gilead’s AZLI Therapy For Treatment Of PALS In Cystic Fibrosis Deemed Safe, Effective In Recent Study

Cystic fibrosis services helps meet demand for high-quality patient care

Underscoring its commitment to the cystic fibrosis (CF) community, Walgreens now offers enhanced personalized therapy management support to help people with CF live healthier lives. Connected CareSM Cystic Fibrosis Management Program is provided through Cystic Fibrosis Continue reading Cystic fibrosis services helps meet demand for high-quality patient care

Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine

– Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations –

SOUTH PLAINFIELD, N.J., May 16, 2014 /PRNewswire/ — PTC Therapeutics, Inc. PTCT -2.85% today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation Continue reading Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine

Vertex says cystic fibrosis drugs shown to boost lung function

(Reuters) – Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, Continue reading Vertex says cystic fibrosis drugs shown to boost lung function

PulmoXen Experimental Cystic Fibrosis Drug From Xenetic Biosciences’ Ends with Positive Results In International Phase 1 Clinical Trial

Massachusetts-based biopharmaceutical company Xenetic Biosciences, Inc. recently reported that it is encouraged by the results of a Phase 1 clinical trial conducted in Russia by its partner, PJSC Pharmsynthez. The trial evaluated Xenetic’s PulmoXenTM, a modified form of recombinant human Continue reading PulmoXen Experimental Cystic Fibrosis Drug From Xenetic Biosciences’ Ends with Positive Results In International Phase 1 Clinical Trial

Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis

Xenetic Biosciences, Inc. XBIO -4.00% , a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the positive results from its Phase I clinical trial of PulmoXenTM for the Continue reading Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis